WORLD Phase 3 trial of Novavax investigational COVID-19 vaccine starts


Phase 3 trial of Novavax investigational COVID-19 vaccine starts


06:56, December 29, 2020

FILE PHOTO: A small shopping basket filled with vials labeled "COVID-19 - Coronavirus Vaccine" and medical sryinges are placed on a Novavax logo in this illustration taken November 29, 2020. Picture taken November 29, 2020. (Photo:Agencies)

WASHINGTON - The Phase 3 trial of another investigational COVID-19 vaccine has begun enrolling adult volunteers, the US National Institutes of Health (NIH) announced on Monday.

The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico.

It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by biotechnology company Novavax, Inc.

Volunteers will be asked to give informed consent prior to their participation in the trial. They will be grouped into two cohorts: individuals 18 through 64 years old and those aged 65 and older, with a goal of enrolling at least 25 percent of all volunteers who are 65 years old or older.

Participants will be followed closely for potential vaccine side effects and will be asked to provide blood samples at specified time points after each injection and during the following two years, according to the NIH.

Scientists will analyze the blood samples to detect and quantify immune responses to SARS-CoV-2, the virus that causes COVID-19.

Novavax is leading the trial as the regulatory sponsor. The US National Institute of Allergy and Infectious Diseases, and the US Biomedical Advanced Research and Development Authority, are funding the trial.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue